Research programme: respiratory disease therapeutics - RespiratoriusAlternative Names: LISA; RCD-007
Latest Information Update: 02 Aug 2016
At a glance
- Originator Respiratorius
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 02 Aug 2016 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Sweden (unspecified route)
- 02 Aug 2016 Discontinued - Preclinical for Acute asthma in Sweden (unspecified route)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-asthma in Sweden